Enrolment characteristics associated with participants who disengaged from the Victorian PrEP implementation study

Ryan KE, Lal L, Roth NJ, Willcox J, Tee BK, Armishaw J, Chang CC, Fairley CK, Cundill P, Forgan-Smith G, Picket C, Gall J, Price B, Murphy DA, Asselin J, Vujovic O, Nguyen L, Locke P, Ruth S, Batrouney C, Cornelisse V, de Wit J, Lockwood JT, El-Hayek C, Stoove M, Hoy JF, Grant RM, Mak A*, Wright EJ*



Background

- PrEPX is an implementation study that aims to emulate real world conditions
 - · Participants attended GP and sexual health clinics for study visits
 - Participants collected study drug from retail pharmacies
 - Participants paid PBS equivalent price for each 3 month of study drug
- Aim of this abstract

To explore characteristics and predictors of passively disengaging with the $\ensuremath{\mathsf{PrEPX}}$ study



Methods

- Included: Participants enrolled in PrEPX Victoria between 26 July 2016 and 30 June 2017
- Excluded: Participants diagnosed at baseline (n=8) or officially withdrew (n=88)
- Data sources:

PrEPX enrolment survey

 Demographics, reasons for enrolling, previous PrEP and PEP use completed at enrolment

Pharmacy data

• Each dispensing of study drug at community pharmacy was recorded Enrolment survey and pharmacy data linked by study id

Analysis

Describe participants with one, two, or three plus PrEP prescriptions dispensed Minimum follow up time nine months (four prescriptions possible) Adjusted logistic regression models



Client characteristics

	1 script dispensed n (%)	2 scripts dispensed n (%)	3+ scripts dispensed n (%)
Participants	241	262	2667
Median days between scripts (IQR)	NA	109 (81-175)	91 (83-102)
Aged 18-24	45 (18.7)	44 (16.8)	229 (8.6)
Ever injected	23 (9.4)	21 (8.0)	114 (4.3)
Previous PrEP use	42 (17.4)	44 (16.8)	730 (27.3)
Previous PEP use	83 (44.4)	109 (41.6)	1081 (40.5)
		A thorne harbour	the Alfred ©@@ @

covariates associated with discligaging nom rich			
One script dispensed			
	aOR*	95% CI	
18-24	2.42	1.73 - 3.39	
25+	Ref		
Yes	2.66	1.71- 4.15	
No	Ref		
No	1.60	1.14 - 2.42	
Yes	Ref		
No	1.30	1.00 - 1.70	
Yes	Ref		
	18-24 25+ Yes No No Yes No	One script aOR* 18-24 2.42 25+ Ref Yes 2.66 No Ref No Ref No 1.60 Yes Ref No 1.30	One script dispensed aOR* 95% CI 18-24 2.42 1.73 - 3.39 25+ Ref 2.66 1.71- 4.15 No Ref 1.60 1.14 - 2.42 Yes Ref 1.30 1.00 - 1.70

Covariates associated with disengaging from PrEPX

*Compared to clients colleting three or more prescriptions over 15 months

Adjusted for all variables presented in table

	VICTORIA State Government	thorne harbour health*	theAlfred 🕑 f 🗓 💿
--	---------------------------------	------------------------------	-------------------

Covariates associated with disengaging from PrEPX

		One script dispensed		Two scripts dispensed	
		aOR*	95% CI	aOR*	95%CI
Age at enrolment	18-24	2.42	1.73 - 3.39	2.07	1.45 - 2.96
	25+	Ref		Ref	
Ever injected drugs	Yes	2.66	1.71- 4.15	2.13	1.31 - 3.48
	No	Ref		Ref	
Previous PrEP use	No	1.60	1.14 - 2.42	1.80	1.28 - 2.53
	Yes	Ref		Ref	
Previous PEP use	No	1.30	1.00 - 1.70	0.92	0.71 - 1.19
	Yes	Ref		Ref	

*Compared to clients colleting three or more prescriptions over 15 months

Adjusted for all variables presented in table

Burnet Institute The Alfred OF CON

Summary of findings and implications

- Participants who were younger, had ever injected, were PrEP and PEP naïve were more likely to disengage
 - Support needed for people who may face barriers to consistent PrEP use
 - Cost, side effects, changing risk



Summary of findings and implications

- Participants who were younger, had ever injected, were PrEP and PEP naïve were more likely to disengage
 - Support needed for people who may face barriers to consistent PrEP use
 - Cost, side effects, changing risk
- Challenges persist in understanding adherence and engagement
 - On-demand use
 - Sharing/lending PrEP when needed
 - Shifting to self-importation during study period

"He ran out of pills and gave them back to me after his next prescription"

CSRH

"To cover them while they were waiting for their shipment to arrive"

the Alfred 🕑 f ம 🎯

Acknowledgements

PrEPX Study Team

Edwina Wright – Principal Investigator

Brian Price Anne Mak Luxi Lal Dean Murphy Jude Armishaw Timmy Lockwood Olga Vujovic Christina Chang Vincent Cornelisse

Burnet Institute

Mark Stoové

Jason Asselin Long Nguyen Carol El-Hayek

CSRH

Dean Murphy, John De Wit

Study Clinics

Prahran Market Clinic: Norm Roth Northside Clinic: Jeff Wilcox MSHC: Kit Fairley PRONTO!: Matt Penn Centre Clinic: BK Tee ERA Health: George Forgan-Smith Alfred HIP Clinic and Nurse Led Clinics

Pharmacies

John Silverii's Pharmacy: John Silverii Newton and Leung Pharmacy: Johnny Phu Melbourne Sexual Health: Anne Mak Alfred Clinical Trials Pharmacy: Anne Mak Healthsmart: Joseph Tesoriero Central Pharmacy: Manoj Vassan, Kie Lim Russell Frajman Pharmacy: Russell Frajman

ACCESS

Burnet Institute, Kirby Institute & NRL

Community Organisations

VAC: Simon Ruth, Colin Batrouney, Jeremy Wiggins PrEP'DForChange: Chris Williams PrEPaccessNOW: Jeff Montgomery & Michael Whelan Living Positive Victoria: Brent Allen Victorian Aboriginal Controlled Community Health Organisation: Kat Byron Centre for Culture Ethnicity and Health: Alison Coelho Harm Reduction Victoria: Jenny Kelsall Funding Bodies

Victorian Department of Health and Human Services: Michael West Alfred Health (Study sponsor): Andrew Way Victorian AIDS Council*: Simon Ruth

Research Participants

PrEPX participants Participants in previous PrEP research



Kathleen Ryan, PhD

HIV Biomedical Prevention Research Fellow, Alfred Health Kathleen.ryan@burnet.edu.au @katlizryan

